786 Antithrombotic Therapy for Management of Early Thrombotic Risk in Transcatheter Aortic Valve Implantation: An Australian Experience

H. Kempton(Broad Institute), David Roy(UNSW Sydney), K. Jones(St Vincent's Hospital Sydney), A Arriagada(St Vincent’s Private Hospital Sydney), J. Carroll(St Vincent's Hospital Sydney), K. Kearney(Collaborative Research Group), D. Baron(St Vincent's Hospital Sydney), N. Bart(St Vincent's Hospital Sydney), David W. Muller(Victor Chang Cardiac Research Institute), T. Meredith(Victor Chang Cardiac Research Institute)
Heart Lung and Circulation
January 1, 2020
10.1016/j.hlc.2020.09.793
Cited by 1

Related Papers

CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
|Cell|2014|2k
Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves
|Circulation|2012|580
Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation
|Journal of the American College of Cardiology|2013|309
Genome-wide association meta-analysis of spontaneous coronary artery dissection identifies risk variants and genes related to artery integrity and tissue-mediated coagulation
|Nature Genetics|2023|92
Standalone balloon aortic valvuloplasty: Indications and outcomes from the UK in the transcatheter valve era
|Catheterization and Cardiovascular Interventions|2012|73